Developmental Research Program

大约50%的新诊断的肉瘤患者最终死于疾病。这个 软组织肉瘤中MSKCC孢子开发研究计划的目的是 支持肉瘤的创新转化研究项目。翻译研究项目 本计划旨在利用动物和人类肉瘤生物学知识来开发和测试 提高软性骨折患者诊断、预后和治疗水平的干预措施 肉瘤。这一计划将使我们能够对翻译研究中的新机会做出快速反应 这将帮助我们招募新的科学人才进入我们的孢子，更广泛地说，进入肌肉瘤 研究。发展研究方案的具体目标是：1)提供 为创新的、由研究人员发起的生物学、发病机制、进展、 和肉瘤的自然史，2)资助具有特殊潜力的研究，以促进 孢子翻译研究的目标，以及3)建立战略研究机制 与其他孢子和其他主要国内和国际研究中心的互动。 我们每年为这个项目预算45万美元，其中包括孢子奖本身的5万美元 以及40万美元的MSKCC机构基金。资金的优先考虑将是那些犯罪分子 被认为是最具创造力和最高科学素质的。将优先考虑项目 这是对孢子长期研究目标的补充，并促进了我们的翻译 研究对象5。执行委员会还可以征集和资助实验或临床 解决软组织肉瘤中MSKCC孢子的紧急和具体需求的倡议 计划或一个独特的研究机会。内部科学咨询委员会，在 马里兰州默里·F·布伦南主席将审查申请，以确定优先使用 这些基金将每年挑选一至两年资助的项目。这些项目 在两年的资助后看起来最有希望将被考虑并入 孢子作为研究项目，无论是在当前或未来的资金周期中。

Approximately 50% of patients with newly diagnosed sarcoma eventually die of disease. The purpose of the Developmental Research Program of the MSKCC SPORE in Soft Tissue Sarcoma is to support innovative translational research projects in sarcoma. The translational research projects in this program aim to use knowledge of animal and human sarcoma biology to develop and test interventions related to improving diagnosis, prognosis, and treatment of pafients with soft fissue sarcoma. This program will allow us to respond quickly to new opportunifies in translational research and will help us recruit new scientific talent into our SPORE and, more broadly, into sarcomarelevant research. The specific aims of the Developmental Research Program are: 1) to provide seed funding for innovative, investigator-initiated research in the biology, pathogenesis, progression, and natural history of sarcoma, 2) to fund research with exceptional potential to advance the translational research goals of the SPORE, and 3) to establish a mechanism for strategic interactions with other SPOREs and other major national and international research centers. We are budgeting $450,000 yeariy for this program including $50,000 from the SPORE award itself and $400,000 in MSKCC institutional funds. The priority for funding will be those inifiafives considered most creafive and of the highest scientific quality. Preference will be given to projects that complement the long-term research goals of the SPORE and advance our translational research objecfives. The executive committee can also solicit and fund experimental or clinical initiatives that address an urgent and specific need in the MSKCC SPORE in Soft Tissue Sarcoma program or a unique research opportunity. The internal scientific advisory committee, under the chairmanship of Murray F. Brennan, MD, will review applications to determine priorities for use of these funds and will annually select projects for one to two years of funding. The projects that appear most promising after two years of funding will be considered for incorporation into the SPORE as Research Projects, either in current or future funding cycles.